Article Information
- Received June 2, 2021
- Revision received January 6, 2022
- Accepted January 8, 2022
- First published January 20, 2022.
- Version of record published March 9, 2022.
Author Information
- Candler Paige1,
- Isabel Plasencia-Fernandez2,
- Moeno Kume1,
- Melina Papalampropoulou-Tsiridou2,
- Louis-Etienne Lorenzo2,
- Eric T. David1,
- Lucy He1,
- Galo L. Mejia1,
- Christopher Driskill1,
- Francesco Ferrini2,3,4,
- Andrew L. Feldhaus5,
- Leon F. Garcia-Martinez5,
- Armen N. Akopian6,
- Yves De Koninck2,4,
- Gregory Dussor1, and
- Theodore J. Price1
- 1Center for Advanced Pain Studies, School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, Texas 75080
- 2CERVO Brain Research Centre, Université Laval, Québec, Québec G1J 2G3, Canada
- 3Department of Veterinary Sciences, University of Turin, 10124 Turin, Italy
- 4Department of Psychiatry and Neuroscience, Université Laval, Québec, Québec G1J 2G3, Canada
- 5Alder BioPharmaceuticals, Bothell, Washington 98011
- 6Department of Endodontics, University of Texas Health San Antonio, San Antonio, Texas 78229-3900
Author contributions
Author contributions: C.P., I.P.-F., L.-E.L., F.F., A.L.F., L.F.G.-M., A.N.A., Y.D.K., G.D., and T.J.P. designed research; C.P., I.P.-F., M.K., M.P.-T., L.-E.L., E.T.D., L.H., G.L.M., and C.D. performed research; C.P., M.P.-T., L.-E.L., F.F., and T.J.P. analyzed data; C.P., Y.D.K., G.D., and T.J.P. wrote the paper.
Disclosures
- Received June 2, 2021.
- Revision received January 6, 2022.
- Accepted January 8, 2022.
This work was supported by National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) Grants NS-102161 (to T.J.P. and A.N.A.), NS-065926 (to T.J.P.), NS-113457 (to C.P.), and NS-104200 (to A.N.A. and G.D.); Alder BioPharmaceuticals (T.J.P.); and Canadian Institutes of Health Research Grant FDN159906 and Canada Research Chair in Chronic Pain and Related Brain Disorders (to Y.D.K.).
A.L.F. and L.F.G.-M. were employees of Alder BioPharmaceuticals. The authors declare no other competing financial interests.
- Correspondence should be addressed to Theodore J. Price at theodore.price{at}utdallas.edu
Funding
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
NS102161; NS065926; NS104200Canadian HIV Trials Network, Canadian Institutes of Health Research (CTN, CIHR)
FDN159906
Other Version
- previous version (January 20, 2022).
- You are viewing the most recent version of this article.
Online Impact